Screener
Nuvation Bio NUVB SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Nuvation Bio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:55 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336646
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales | 911 | 172 | 1,286 | 172 |
| Cost of collaboration and license agreements revenue | 8,560 | 2,404 | 14,176 | 4,498 |
| Research and development | 30,661 | 27,362 | 65,708 | 51,963 |
| Selling, general and administrative | 42,591 | 38,484 | 80,900 | 73,877 |
| Total costs and expenses | 82,723 | 68,422 | 162,070 | 130,510 |
| Loss from operations | (51,036) | (63,589) | (47,155) | (122,593) |
| Other income (expense): | ||||
| Interest income | 4,596 | 4,780 | 9,704 | 10,101 |
Item 1. Financial Statements.
FAQ
- What is Nuvation Bio's SG&A?
- Nuvation Bio (NUVB) reported SG&A of $42.59M in Q2 2026.
- How has Nuvation Bio's SG&A changed year-over-year?
- Nuvation Bio's SG&A increased by 10.7% year-over-year, from $38.48M to $42.59M.
- What is the long-term trend for Nuvation Bio's SG&A?
- Over 2 years (2023 to 2025), Nuvation Bio's SG&A has grown at a 130.5% compound annual growth rate (CAGR), from $28.53M to $151.56M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Nuvation Bio's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude